CD40 Ligand Blockade for Prevention of Graft-Versus-Host Disease This scoping review was conducted based on the Arksey and O'Malley framework and the work of Levac et al. The databases searched ...

Background: PV is characterized by red blood cell overproduction. Rusfertide is a subcutaneous (SC), self-injected, first-in-class peptide hepcidin mimetic that decreases erythrocytosis. VERIFY ...

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer Despite ...

C-144-01 (ClinicalTrials.gov identifier: NCT02360579) is a phase II study of lifileucel in patients with advanced melanoma who progressed on or after anti–PD-1/PD-L1 therapy. 10 Study design, methods, ...

For the purpose of this paper, we define oncology rehabilitation as services provided by licensed medical providers (eg, physical or occupational therapists, physical medicine and rehabilitation ...

Breast cancer is the most common cancer diagnosed in women, making it the second most commonly diagnosed cancer in the world. 1,2 About 2.3 million new breast cancer cases and 685,000 deaths occurred ...

Hepatocellular carcinoma (HCC) is a lethal malignancy that is subtle neither in its clinical presentation nor in its aggressive course. Numerous diagnostic guidelines have focused on noninvasive ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free survival (HR 0.79, 95% CI 0.66–0.95) and overall ...

The National Cancer Institute defines rare cancer as a cancer with an incidence rate <15 per 100,000 people; recently, the term “ultra-rare cancer” was defined as cancer with an incidence rate <1 × 10 ...

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human ...

PURPOSEAdolescents and young adults (AYAs) with cancer are susceptible to financial hardship during and after a cancer diagnosis. Implementing systematic financial screening is essential to ...